Plozalizumab (INN; hu1D9) is a humanized monoclonal antibody designed for the treatment of diabetic nephropathy and arteriovenous graft patency.[1][2]
This drug was developed by Takeda Pharmaceuticals International Co.
Immune activation: Dostarlimab Other: Ibalizumab
This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.